Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2020 (Event Date)
Reporting Period: The filing details a capital raise transaction closed on April 17, 2020, following the entry into a purchase agreement on April 14, 2020.
Key Financial Metrics and Transaction Details
This filing reports the issuance of debt securities rather than standard operating financial results (revenue, profit, or cash flow from operations are not provided in this document).
- Debt Issuance: $200,000,000 aggregate principal amount of 1.500% Convertible Senior Subordinated Notes due 2026.
- Over-Allotment Option: Initial purchasers hold an option to purchase up to an additional $30,000,000 principal amount of Notes.
- Interest Rate: 1.500% per annum, payable semi-annually in arrears starting October 15, 2020.
- Maturity Date: April 15, 2026.
- Conversion Terms: Initial conversion rate of 51.9224 shares per $1,000 principal amount (approx. $19.26 per share).
- Capped Call Transactions: The Company entered into capped call transactions with a cost of $15.8 million. The initial cap price is $25.9263 per share (approx. 75% premium over the April 14, 2020 closing price).
- Maximum Dilution: Up to 15,524,793 shares of common stock may be issued upon conversion if the over-allotment option is fully exercised.
Material Changes Versus Prior Period
This filing represents a discrete capital event rather than a period-over-period operational comparison. The material change is the addition of $200 million in unsecured, subordinated indebtedness to the Company's balance sheet and the establishment of a capped call hedge to offset potential dilution from the convertible notes.
Guidance, Outlook, Risks, and Contingencies
- Redemption: The Company may not redeem the Notes at its option before maturity.
- Fundamental Change Repurchase: If a "Fundamental Change" (e.g., business combination or delisting) occurs, noteholders may require the Company to repurchase the Notes at 100% of principal plus accrued interest.
- Events of Default: Includes payment defaults (with a 30-day cure period for interest), failure to comply with covenants regarding asset transfers, defaults on other indebtedness exceeding $20 million, and bankruptcy/insolvency events.
- Subordination: The Notes are subordinated to "Designated Senior Indebtedness" and structurally subordinated to all liabilities of the Company's subsidiaries.
- Use of Proceeds: The filing does not explicitly detail the specific operational use of proceeds beyond funding the capped call transactions if the over-allotment is exercised.
Investor Verification Checklist
- Verify the final closing amount, specifically whether the $30 million over-allotment option was exercised.
- Confirm the current market price of CHRS common stock relative to the $19.26 conversion price and $25.9263 cap price to assess dilution risk.
- Review the Company's existing "Designated Senior Indebtedness" to understand the subordination hierarchy.
- Monitor the Company's cash position to ensure ability to service the semi-annual interest payments starting October 2020.
- Check for any subsequent filings regarding the "Make-Whole Fundamental Change" provisions if corporate restructuring is anticipated.